Multipronged approach identifying new hallmarks of antibiotics-mediated immunosuppression in a prospective cancer immunotherapy trial

The Immunolife1 (IML1) project aimed at prospectively analyzing the clinical outcomes and biological effects of ATB across three distinct malignancies amenable to ICI-based therapies. Samples were prospectively collected at ONCOBIOTICS (NCT04567446) study.

Immunolife1 (IML1) 项目旨在前瞻性分析ATB在三类适合接受基于免疫检查点抑制剂（Immune Checkpoint Inhibitor，ICI）治疗的不同恶性肿瘤中的临床结局与生物学效应。所有样本均前瞻性采集自ONCOBIOTICS（NCT04567446）研究。